Jazz Pharmaceuticals plc SEC Filing
Jazz Pharmaceuticals plc has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 2,741 shares of common stock with an aggregate market value of $662,143.37 by an individual through Morgan Stanley Smith Barney LLC, acquired via a stock option exercise on May 22, 2026. This notice confirms that the person selling the securities does not know of any material adverse information about the issuer that has not been publicly disclosed.
Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley analyst Sean Laaman and Raymond James analyst Tiago Fauth both raised their price targets for Jazz Pharmaceuticals (JAZZ) after the company reported strong Q1 results and saw its shares rise about 25% year-to-date. The company's performance was bolstered by sustained demand for Xywav, growth in rare oncology launches, and anticipated catalysts like the potential launch of zanidatamab. Jazz Pharmaceuticals also maintained its full-year 2026 revenue guidance.
How Investors Are Reacting To Jazz Pharmaceuticals (JAZZ) Reaffirmed Guidance And Rare-Disease Portfolio Momentum
Jazz Pharmaceuticals recently reported a strong Q1 2026, driven by key product growth in its sleep, epilepsy, and oncology franchises, leading management to reaffirm full-year guidance and emphasize rare disease expansion. While the strong performance and reiterated outlook highlight the company's diversified portfolio and capital planning, investors are still weighing the long-term dependence on a concentrated portfolio against the looming threat of oxybate generics and potential margin pressure. Analysts offer varied perspectives, with some forecasting substantial growth and a fair value, while others remain cautious due to patent expirations and potential pricing pressure.
JAZZ Upgraded by UBS -- Price Target Raised to $307
UBS analyst Ashwani Verma has upgraded Jazz Pharmaceuticals (JAZZ) from "Neutral" to "Buy" and raised the price target significantly from $188 to $307. While the upgrade reflects strong confidence in the company's growth potential and strategic initiatives, Jazz Pharmaceuticals is currently considered overvalued by 54.9% according to GuruFocus's GF Value™, and recent insider activity shows $16.5 million in shares sold.
Jazz Pharmaceuticals (JAZZ) Upgraded to Buy by UBS with Target Price of $307
UBS has upgraded Jazz Pharmaceuticals (JAZZ) to "Buy" with a target price of $307, citing confidence in its core business and the commercial potential of a new cancer treatment, Ziihera. Despite this, GuruFocus indicates the stock is 51.0% overvalued at its current price of $229.55, and recent insider activity shows significant selling. Investors are advised to exercise caution due to the high valuation and insider selling, despite strong profitability and growth metrics.
Jazz Pharma raised to Buy at UBS on Ziihera potential
UBS has upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral, attributing the decision to the strong commercial potential of Ziihera, the company's FDA-approved therapy for biliary tract cancer. The upgrade led to a higher trading volume for Jazz Pharmaceuticals on Tuesday.
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings Signal Promising Growth Potential
Jazz Pharmaceuticals plc (JAZZ) is highlighted for its strong market performance and growth potential, driven by a diverse portfolio of therapies for conditions like narcolepsy and cancer. The company boasts robust financial metrics, including a market cap of $14.35 billion, substantial free cash flow, and a positive outlook from analysts with numerous "buy" ratings and a promising target price. Strategic collaborations and pipeline developments further underscore its potential for continued upward trajectory in the biotech sector.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Strong Q1 Earnings And Upcoming FDA And Study Catalysts
Jazz Pharmaceuticals (JAZZ) reported strong Q1 earnings with revenues of US$1,068.9 million and net income of US$293.1 million, reaffirming full-year guidance and highlighting upcoming FDA and study milestones. The stock has seen significant returns over the past year, with analysts generally pegging its fair value at $225.53, slightly below its current trading price, suggesting it is about 1% overvalued. Despite this, the stock's price-to-sales ratio is below the industry average, indicating either investor caution due to risks like generic competition or an incomplete repricing of recent positive developments.
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al
Virginia Retirement Systems ET Al significantly reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 41.1% in the fourth quarter, selling 9,730 shares. Insider selling has also been notable, with officers selling 74,015 shares totaling $14.18 million over the past 90 days. Despite these sales, analysts largely maintain a "Moderate Buy" rating with an average price target of $230.56, even as the stock traded down 1% to $228.77.
Truist Financial Corp Has $1.86 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ
Truist Financial Corp significantly reduced its stake in Jazz Pharmaceuticals PLC by 66.5% in the fourth quarter, ending with holdings valued at about $1.86 million. Despite strong recent earnings from Jazz Pharmaceuticals and a "Moderate Buy" consensus rating from Wall Street analysts, insider selling has been noted. The company's stock performance and institutional ownership are also detailed, alongside analyst price target adjustments.
Jazz Pharmaceuticals stock hits all-time high at $230.85 By Investing.com
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $230.85, reflecting significant investor confidence and strong performance, including a 121% total return over the last year. RBC Capital has raised its price target to $258, maintaining an Outperform rating, following the company's strong Q1 2026 financial results that exceeded earnings expectations with $1.1 billion in revenue. InvestingPro analysis suggests the stock remains undervalued despite its record-breaking price.
Jazz Pharmaceuticals stock hits all-time high at $230.85
Jazz Pharmaceuticals (JAZZ) stock reached an all-time high of $230.85, a 121% total return over the last year, driven by strong growth and investor confidence. The company reported robust Q1 2026 financial results with $1.1 billion in revenue, leading RBC Capital to raise its price target to $258. InvestingPro analysis suggests the stock is undervalued, with analysts revising earnings upwards due to its diversified portfolio strength.
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
Jazz Pharmaceuticals stands out from traditional cannabis companies through its FDA-approved drug Epidiolex, a cannabidiol therapy for epilepsy. Epidiolex contributes significantly to Jazz's sales, and the company is expanding its reach while also benefiting from a diversified portfolio including neuroscience and oncology products. Although facing some pipeline setbacks, Jazz appears well-positioned due to Epidiolex's established commercial status and its broader pharmaceutical offerings, making it a potentially lower-risk investment in cannabinoid-based therapeutics.
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
Jazz Pharmaceuticals' recent earnings report, while showing soft profit numbers, was positively received by the market due to underlying factors. The company exhibited a strong accrual ratio of -0.16, indicating statutory earnings were significantly less than free cash flow, and its profit was reduced by US$1.5 billion in unusual items, which often represent one-off charges. Additionally, a US$249 million tax benefit further contributed to the complexity of interpreting its reported profit, suggesting the actual earnings potential might be better than it appears.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc announced its upcoming participation in three investor conferences in May and June 2026: the RBC Global Healthcare Conference, the TD Cowen 7th Annual Oncology Innovation Summit, and the Jefferies Global Healthcare Conference. Audio webcasts of the fireside chats will be available on the company's investor relations website, with replays archived for 30 days. The company, headquartered in Dublin, Ireland, focuses on developing medicines for rare diseases, including therapies for epilepsies, cancers, and sleep disorders.
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
This article is missing content. A summary cannot be generated.
Three Jazz Pharmaceuticals investor webcasts set for May–June 2026
Jazz Pharmaceuticals (Nasdaq:JAZZ) announced its participation in three upcoming investor conferences in May and June 2026. The company's management will hold fireside chats at the RBC Global Healthcare Conference, the Cowen 7th Annual Oncology Innovation Summit, and the Jefferies Global Healthcare Conference. Audio webcasts of these events, along with replays, will be accessible through the Investors section of Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc announced its participation in three upcoming investor conferences in May and June 2026. Company management will engage in fireside chats at the RBC Global Healthcare Conference, the TD Cowen 7th Annual Oncology Innovation Summit, and the Jefferies Global Healthcare Conference. Audio webcasts and replays of these events will be available on the company's investor relations website.
Here’s What Analysts Are Saying About Jazz Pharmaceuticals (JAZZ) Post Q1 Results
Jazz Pharmaceuticals (JAZZ) received positive rating updates from Raymond James and TD Cowen after reporting strong Q1 2026 financial results, with total revenues up 19% year-over-year to $1.1 billion. Raymond James increased its price target to $239, while TD Cowen raised its target to $275, both reaffirming Buy/Outperform ratings. Analysts noted the company's transformation towards an innovation-led biotech focus.
Jazz Pharmaceuticals (JAZZ) Is Up 8.5% After Q1 Profit Rebound And Ziihera Priority Review – Has The Bull Case Changed?
Jazz Pharmaceuticals experienced an 8.5% rise after reporting a significant rebound in Q1 2026 profits and receiving Priority Review from the FDA for its oncology drug, Ziihera. The company swung from a net loss to a net income of US$293.1 million, with earnings per share reaching US$4.43. This positive development, particularly Ziihera's potential in HER2-positive gastric cancer, is crucial for Jazz Pharmaceuticals as it aims to expand its oncology portfolio and mitigate patent pressures on its sleep franchise.
Jazz Pharmaceuticals (JAZZ) Is Up 8.5% After Q1 Profit Rebound And Ziihera Priority Review – Has The Bull Case Changed?
Jazz Pharmaceuticals experienced an 8.5% stock increase following a significant Q1 2026 profit rebound, turning a US$92.5 million net loss into US$293.1 million in net income, and the FDA's Priority Review acceptance for its oncology drug Ziihera. This development could reshape the company's investment narrative by strengthening its oncology portfolio, but investors still face risks from upcoming generic competition to its sleep franchise. The article explores how this news affects the long-term outlook for Jazz Pharmaceuticals, which aims for substantial revenue and earnings growth by 2029.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Surge
Jazz Pharmaceuticals (JAZZ) has seen a significant surge in its share price, with a 19% increase over the past month and 37% over three months. While a narrative valuation suggests the stock is approximately 1% overvalued at $225.53, a Discounted Cash Flow (DCF) model indicates it might be undervalued by about 72% with a value of $808.36. The discrepancy highlights varying interpretations of the company's future growth potential, R&D investments, and market risks, urging investors to conduct their own detailed analysis.
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc recently exceeded analyst expectations, reporting strong Q1 earnings with revenues of US$1.1 billion and EPS of US$4.43. Following these positive results, analysts have become more optimistic, upgrading their earnings per share estimates for 2026 and increasing the consensus price target to US$242. Despite the positive outlook, the company's revenue growth is projected to slow down significantly compared to its historical performance and the wider industry.
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc exceeded earnings expectations, with revenue of US$1.1 billion and statutory EPS of US$4.43. Analysts have subsequently become more bullish, increasing their earnings per share estimates and raising the consensus price target to US$242. Despite strong immediate results and revised forecasts, the company's revenue growth is projected to slow compared to historical rates and the wider industry.
Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here’s What’s Driving the Move
Jazz Pharmaceuticals (JAZZ) saw its stock surge 105% over the past year, driven by strong Q1 2026 results with a significant EPS beat and 19% revenue growth, alongside an advancing oncology franchise including the FDA's priority review for Ziihera. Analysts project the stock could rise to $284 per share by December 2028, representing a 24.1% total return, based on its durable sleep disorder franchise, accelerating oncology commercialization, and high operating margins. The article emphasizes key catalysts like Ziihera's commercialization progress and Zepzelca's approval for continued investor returns.
Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives
Jazz Pharmaceuticals reported strong Q1 2026 results with basic EPS of US$4.74 and US$1.1 billion in revenue, challenging bearish narratives about its margins. Despite a US$1.5 billion one-off loss impacting its trailing 12-month net income, bulls point to recent quarterly profitability and five-year earnings growth as signs of underlying strength. The company's stock also trades at a discount compared to peers and its DCF fair value, with analysts projecting significant future earnings growth.
Jazz Pharmaceuticals Q1 2026 Earnings Results and Conference Call - News and Statistics
Jazz Pharmaceuticals plc announced its financial results for the first quarter of 20
Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
Jazz Pharmaceuticals (JAZZ) is reiterated as a Strong Buy due to robust Q1 2026 results and its successful pivot into oncology, particularly with drugs like Ziihera and Modeyso driving double-digit sales growth. Despite a 40% rally, the stock is still considered undervalued, trading at approximately 9x 2026 earnings, suggesting significant upside potential as the market underappreciates its oncology-driven growth. The company's Ziihera is poised for substantial market expansion with a Priority Review for HER2+ GEA and multiple late-stage trials, potentially reaching over $2 billion in peak sales.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its Q1 2026 earnings, exceeding expectations with an EPS of $6.34 versus $4.67. The company announced record first-quarter revenues of $1.1 billion, a 19% year-over-year increase, driven by strong performance from Xywav, Epidiolex, Midevo, and Zepzelca. Jazz Pharmaceuticals reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion and highlighted advancements in its pipeline, including the priority review of zanidatumab for HER2-positive first-line metastatic GEA.
Bruce Cozadd sells 6,000 Jazz (NASDAQ: JAZZ) shares under 10b5-1 plan
Bruce C. Cozadd, a director at Jazz Pharmaceuticals plc, sold 6,000 Ordinary Shares at $203.33 per share on May 1, 2026. This transaction was executed automatically under a pre-arranged 10b5-1 trading plan adopted in November 2025, meaning it was not a discretionary decision by Cozadd. Following the sale, he directly holds 378,682 Ordinary Shares.
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Reports Q1 Revenue $1.07B, vs. FactSet Est of $978.5M
Jazz Pharmaceuticals plc announced its Q1 revenue reached $1.07 billion, exceeding FactSet's estimate of $978.5 million. The company's stock, JAZZ, closed at $212.26, showing a positive performance year-to-date. This strong financial result highlights the company's robust market position and effective business strategies.
Jazz Pharmaceuticals plc 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:JAZZ) 2026-05-05
Jazz Pharmaceuticals plc published its Q1 2026 earnings call presentation on May 5, 2026. The slide deck was released in conjunction with their earnings call. Seeking Alpha's transcripts team prepared this content.
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Jazz Pharmaceuticals reported record first-quarter revenue of $1.07 billion, driven by 45% growth in its oncology portfolio and strong performances from Zebselka, Modezo, and Epidiolex. The company reaffirmed its 2026 revenue guidance of $4.25 billion to $4.5 billion, while anticipating increased competition in the sleep business. Significant R&D efforts are underway, particularly for zanadatamab in breast cancer, with the company maintaining a strong balance sheet for future investments and potential acquisitions.
Jazz Pharmaceuticals surges on earnings beat, strong revenue
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported first-quarter results that surpassed Wall Street expectations, with adjusted earnings per share of $6.34 and revenue of $1.07 billion, marking a 19% year-over-year growth. The company reaffirmed its full-year 2026 revenue guidance, and its shares rose 4.8% in after-hours trading following the announcement. Key products like Xywav, Epidiolex, Zepzelca, and Modeyso all contributed to significant revenue growth, and the FDA has accepted a supplemental Biologics License Application for zanidatamab under Priority Review.
Jazz: Q1 Earnings Snapshot
Jazz Pharmaceuticals PLC (JAZZ) reported first-quarter net income of $293.1 million, or $4.43 per share, significantly exceeding Wall Street's expectations. Adjusted earnings per share were $6.34, and the company posted revenue of $1.07 billion, also surpassing forecasts. Jazz now projects full-year revenue to be between $4.25 billion and $4.5 billion.
Jazz Pharmaceuticals (NASDAQ: JAZZ) swings to Q1 2026 profit on PRV sale
Jazz Pharmaceuticals reported a significant financial turnaround in Q1 2026, swinging to a net income of $293.1 million from a net loss of $92.5 million in the prior year, largely driven by a $122.8 million gain from the sale of a rare pediatric disease priority review voucher and robust revenue growth across its sleep, epilepsy, and oncology franchises. Total revenues climbed to $1,068.9 million, up from $897.8 million, with strong performances from Xywav, Epidiolex/Epidyolex, and oncology products like Zepzelca and the newly launched Modeyso and Ziihera. The company maintains significant liquidity with $2.9 billion in cash and investments, despite a total debt of $5.4 billion, and continues to invest heavily in R&D and strategic acquisitions to support its rare disease pipeline.
All eyes on Jazz Pharmaceuticals earnings as FDA decision nears
Jazz Pharmaceuticals PLC is set to report first-quarter earnings, with investors closely watching its diversification strategy and the upcoming FDA decision on zanidatamab. Analysts expect an EPS of $4.62 on revenue of $981.1 million, reflecting a sequential decline from the previous quarter but strong year-over-year growth. The company's oncology portfolio, especially zanidatamab, and the sustained performance of neuroscience franchises like Epidiolex and Xywav, are key areas of focus.
Jazz Pharmaceuticals stock hits all-time high at 207.49 USD
Jazz Pharmaceuticals PLC (JAZZ) stock has reached an all-time high of $207.49, reflecting a 71.52% increase over the past year. The biopharmaceutical company, valued at $12.75 billion, is considered undervalued by InvestingPro, with a fair value of $261.38, suggesting further growth potential. Analysts expect the company to be profitable this year, with strong performance driven by products like Xywav, Epidiolex, and Modeyso, and a promising regulatory filing for Ziihera.
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Mitsubishi UFJ Trust & Banking Corp
Mitsubishi UFJ Trust & Banking Corp reduced its stake in Jazz Pharmaceuticals by 19.1% during the fourth quarter, selling 9,703 shares and now holding 41,166 shares valued at approximately $6.99 million. Despite this, other institutions like Goldman Sachs and Royal Bank of Canada significantly increased their positions, leading to hedge funds and institutional investors owning about 89.14% of the stock. Insiders sold a total of 74,015 shares worth $14.18 million in the last quarter, while analysts maintain a "Moderate Buy" rating with an average price target of $216.87.
Vanguard Group Inc. Buys 10,197 Shares of Jazz Pharmaceuticals PLC $JAZZ
Vanguard Group Inc. increased its stake in Jazz Pharmaceuticals PLC by 0.2% in the fourth quarter, purchasing an additional 10,197 shares to own a total of 5,917,142 shares valued at over $1 billion. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $216.87. The company reported strong quarterly earnings and revenue, exceeding analyst expectations, and institutional investors now hold 89.14% of the stock.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone
Jazz Pharmaceuticals (JAZZ) is gaining attention after its Ziihera supplemental biologics application received priority review from US regulators for HER2-positive advanced gastroesophageal cancers, supported by strong Phase 3 data. The stock has seen significant returns over the past year, trading below the average analyst price target. The company's valuation of $225.53 suggests it is 10.1% undervalued, with future growth expected from new therapy approvals and international expansion, though risks like Oxybate competition and trial delays could impact this outlook.
Jazz Pharmaceuticals (NASDAQ: JAZZ) reports two 6,000-share Rule 144 sales
Jazz Pharmaceuticals (NASDAQ: JAZZ) has reported two Rule 144 sales of restricted common stock, each for 6,000 shares. These transactions, filed in a Form 144, occurred on March 3, 2026, and April 1, 2026, and were conducted by Bruce Cozadd. The filing provides notification of restricted-stock sales without indicating any unusual activity or specific proceeds to Jazz Pharmaceuticals.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Sees Significant Decline in Short Interest
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) experienced a significant 19.7% decline in short interest during April, reaching 5,240,459 shares as of April 15th. The stock's short-interest ratio is now 6.0 days, with approximately 8.9% of its shares sold short. Despite insider selling, institutional ownership remains high at 89.14%, and analysts maintain a "Moderate Buy" rating with an average target price of $216.87.
Pictet Asset Management Holding SA Sells 33,547 Shares of Jazz Pharmaceuticals PLC $JAZZ
Pictet Asset Management Holding SA reduced its stake in Jazz Pharmaceuticals PLC by 15.4%, selling 33,547 shares and now owning 184,696 shares valued at $31.487 million. Company insiders have also been net sellers, with Director Bruce C. Cozadd and Director Norbert G. Riedel selling significant amounts of shares. Despite insider selling, analyst sentiment for Jazz Pharmaceuticals is largely positive, with a "Moderate Buy" consensus rating and an average target price of $216.87.
Vanguard Capital Management reports 5.04% stake in Jazz Pharmaceuticals (NASDAQ: JAZZ)
Vanguard Capital Management has reported a 5.04% beneficial ownership stake in Jazz Pharmaceuticals (NASDAQ: JAZZ), translating to 3,103,522 shares of common stock. This Schedule 13G filing indicates a passive investment, with Vanguard having sole voting power over 455,189 shares and sole dispositive power over all 3,103,522 shares. The official signature date for the filing is April 30, 2026.
Will Ziihera’s Priority Review in First-Line HER2-Positive Gastric Cancer Shift Jazz Pharmaceuticals’ (JAZZ) Narrative?
Jazz Pharmaceuticals has announced that the FDA granted Priority Review to Ziihera for first-line treatment of HER2-positive gastric cancers, with a PDUFA date of August 25, 2026. This move aims to expand Ziihera's use beyond biliary tract cancer and is supported by strong Phase 3 data and Breakthrough Therapy designation. The company's investment narrative will now heavily focus on these oncology outcomes amidst pressures from upcoming generic competition for its sleep products.
M&T Bank Corp Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ
M&T Bank Corp recently acquired 11,172 shares of Jazz Pharmaceuticals, valued at approximately $1.9 million, making it a new institutional investor in the company. Institutional investors now hold approximately 89.14% of the stock, while company insiders have been net sellers. Jazz Pharmaceuticals also reported strong Q4 results, surpassing earnings estimates and receiving a "Moderate Buy" consensus rating from analysts with an average price target of $216.87.
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer By Investing.com
Jazz Pharmaceuticals announced that the FDA accepted its supplemental Biologics License Application for Ziihera for the first-line treatment of HER2-positive gastric, gastroesophageal junction, or gastroesophageal adenocarcinoma, granting it Priority Review. The FDA has set a target action date of August 25, 2026. This news comes as Jazz shares have surged 77% over the past year, and the company's financial outlook appears strong, with analysts forecasting earnings growth and high gross profit margins.
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals announced that the FDA has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) combinations to treat first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date of August 25, 2026. The submission is supported by data from the HERIZON-GEA-01 trial and is currently under review via the Real-Time Oncology Review program.
Universal Beteiligungs und Servicegesellschaft mbH Has $15.32 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Jazz Pharmaceuticals PLC, now holding $15.32 million worth of shares. This comes amidst recent insider selling by company executives, while analysts maintain a "Moderate Buy" rating for Jazz Pharmaceuticals with an average price target of $216.87. The company recently reported strong quarterly earnings, beating analyst expectations.
